Apellis Pharma gained more than 12%, boosted by interim data from its ongoing phase Ib trial evaluating APL-2 in subcutaneous formulation as a monotherapy in paroxysmal nocturnal hemoglobinuria, dubbed PADDOCK.
Original Article: APVO Walks The Talk, Eleven Bio Gains Over 13%, PADDOCK Data Boosts APLS